Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT ID: NCT02296190

Last Updated: 2020-12-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 199 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-27
• Study Completion Date: 2016-12-31

Brief Summary

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the effects of 4 different doses of MSP-2017 (Etripamil) in subjects with paroxysmal supraventricular tachycardia. It includes an up to 21-day Screening Period, a 1-day Treatment Visit, and either a Follow-up Visit or Early Termination Visit occurring 12 hours to 5 days after the Treatment Visit. Subjects will be randomized to yield at least 100 evaluable subjects distributed into 5 groups of at least 20 subjects each.

Conditions

Paroxysmal Supraventricular Tachycardia (PSVT)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Etripamil

1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)

Group Type: EXPERIMENTAL

Etripamil

Intervention Type: DRUG

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Placebo

1 dose of placebo via 4 intranasal applications at time 0

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Interventions

Etripamil

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Intervention Type: DRUG

Placebo

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Intervention Type: DRUG

Other Intervention Names

MSP-2017

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18 years and older at Screening
• Has a history of PSVT
• Is scheduled for an electrophysiology study and catheter ablation
• Has provided written informed consent
• Agrees to use a medically accepted form of contraception or abstinence to prevent pregnancy. Males must agree to use an acceptable form of contraception or abstinence from the time of study drug administration through the Follow-up Visit. Females must agree to use an acceptable form of contraception or abstinence from Screening until 30 days following study drug administration. Post-menopausal female subjects must be amenorrheic for ≥ 12 months prior to Screening or ≥ 6 weeks post-surgical bilateral oophorectomy (with or without hysterectomy) prior to Screening, if they do not wish to use an acceptable form of contraception or abstinence. Acceptable forms of contraception include: A condom and an intrauterine device; A condom and hormonal contraception; A condom and a diaphragm; Sterilization of the subject or the subject's partner(s) (sterilization procedure must have been performed 3 or more months prior); Hysterectomy of the subject or the subject's partner(s)
• If a female of childbearing potential: Has a negative serum pregnancy test result at Screening (Screening must occur ≥7 days prior to randomization [ie, on or before Day -7]) and at the Treatment Visit (pre-PSVT induction); Has had a menstrual period within 28 days of the Treatment Visit.

Exclusion Criteria

• Has a history of serious allergic reaction to verapamil (especially when administered intravenously) including rash, itching or swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing
• Is currently participating in another drug or device study, or has received an investigational drug or device within 30 days of Screening
• Has evidence of clinically significant cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, pulmonary, psychiatric, or renal disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of study results
• Is a female who is breast feeding, pregnant, or planning to become pregnant during the study period
• Has evidence of any clinically significant acute or chronic condition of the nasal cavity (e.g., rhinitis or deviated septum) which could interfere with IN administration of the study drug in either or both nasal cavities
• Has any of the following at screening or at the Treatment Visit: Systolic blood pressure <100 mmHg, Diastolic blood pressure <50 mmHg
• Has evidence of hepatic impairment, defined as: Alanine aminotransferase or aspartate aminotransferase levels that are greater than or equal to 3× upper limit of normal (ULN) or Bilirubin levels that are greater than or equal to 2× ULN, unless due to Gilbert's syndrome
• Has evidence of renal impairment, defined as an estimated glomerular filtration rate <30 mL/min (Modification of Diet in Renal Disease method)
• Has taken digoxin, verapamil, diltiazem, or any Class I, II (e.g., beta blockers), or III antiarrhythmic drug less than the equivalent of 5 half-lives of this drug prior to the Treatment Visit
• Has taken amiodarone within 30 days of the Treatment Visit
• Has taken drugs of abuse which, in the opinion of the Investigator, would impact the validity of study results
• Has had myocardial infarction, percutaneous coronary intervention, cerebrovascular accident, transient ischemic attack, unstable angina, or acute decompensation of heart failure within 6 months of Screening
• Has a history or evidence of second- or third-degree atrioventricular block
• Has an implanted device (e.g., pacemaker, or implantable cardioverter defibrillator) that precludes study participation in the opinion of the Investigator and Study Medical Monitor
• Has a history or evidence of preexcitation syndrome (e.g., Wolff-Parkinson- White syndrome, short PR, etc.)
• Has evidence of a QT interval (Bazett's correction) (QTcB) >455 milliseconds at Screening or at the Treatment Visit
• Has a history or evidence of familial long QT syndrome, torsades de pointes, ventricular fibrillation, sustained ventricular tachycardia, Brugada syndrome, or sudden cardiac death
• Has evidence of recurrent or chronic atrial tachycardia, atrial flutter, or atrial fibrillation; that could interfere with the current investigation; or
• Has a history or evidence of congestive heart failure (except New York Heart Association Class I) or pulmonary edema

In addition, randomized subjects who meet any of the following criteria at the Treatment Visit (Day 1) prior to study drug administration, will be excluded from participation in the study:

• PSVT cannot be induced or the mechanism of PSVT is neither Atrioventricular reentrant tachycardia (AVRT) nor Atrioventricular nodal reentry tachycardia (AVNRT)
• It is not possible to sustain an episode of PSVT for 5 minutes
• The subject requires a continuous sedative (e.g., propofol), continuous analgesic, or inhaled anesthetic at any point until time 30. Minimally necessary dose(s) of benzodiazepine(s) (e.g., midazolam) and/or narcotic(s) (e.g., fentanyl) (given via single or multiple administration[s]) may be used at the Investigator's discretion. The identity(-ies) and actual administered dose(s) of any benzodiazepine(s) and/or narcotic(s) should be recorded in the study documentation. Local anesthetic(s) may be used at the Investigator's discretion; any use should be recorded in the study documentation
• The subject has undergone prior ablation, and the subject's atrioventricular node function is abnormal in the opinion of the Investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medpace, Inc.

INDUSTRY

Sponsor Role: collaborator

Milestone Pharmaceuticals Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Francis Plat

Role: STUDY_DIRECTOR

Chief Medical Officer

Locations

Arizona Heart Rhythm Center

Phoenix, Arizona, United States

Mayo Clinic Arizona

Phoenix, Arizona, United States

Mercy General Hospital

Sacramento, California, United States

South Denver Cardiology Associates

Littleton, Colorado, United States

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Memorial Hospital Jacksonville

Jacksonville, Florida, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Northside Hospital

St. Petersburg, Florida, United States

University of South Florida Health South Tampa Center

Tampa, Florida, United States

Piedmont Atlanta Hospital

Atlanta, Georgia, United States

Emory University Hospital

Atlanta, Georgia, United States

Iowa Heart Center

West Des Moines, Iowa, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

MedStar Health Research Institute

Baltimore, Maryland, United States

Mayo Clinic

Rochester, Minnesota, United States

Aultman Hospital Cardiology Clinical Trials

Canton, Ohio, United States

University of Cincinnati Medical Center Division of Cardiovascular Diseases

Cincinnati, Ohio, United States

ProMedica Toledo Hospital

Toledo, Ohio, United States

Great Lakes Medical Research, LLC

Willoughby, Ohio, United States

Black Hills Cardiovascular Research

Rapid City, South Dakota, United States

Texas Cardiac Arrhythmia Research Foundation

Austin, Texas, United States

Baylor St. Luke's Hospital

Houston, Texas, United States

Houston Methodist Hospital

Houston, Texas, United States

University of Virginia Medical Center

Charlottesville, Virginia, United States

Centra Stroobants Cardiovascular Center

Lynchburg, Virginia, United States

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Sunnybrook Health Sciences Center

Toronto, Ontario, Canada

St. Michael's Hospital

Toronto, Ontario, Canada

The Montreal Heart Institute

Montreal, Quebec, Canada

CHUM Hotel Dieu

Montreal, Quebec, Canada

Countries

United States; Canada

References

Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondesert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082.

Reference Type: DERIVED

PMID: 30049309 (View on PubMed)

Other Identifiers

MSP-2017-1109

Identifier Type: -

Identifier Source: org_study_id